UK Neurology Clinical Trials Market Report 2022 to 2030

UK Neurology Clinical Trials Market Analysis

$ 3999

The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The market will be driven by increasing funding and assistance from institutions such as the NIHR as well as greater awareness and understanding of neurological disorders. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Biogen Inc & Cambridge Cognition Holdings PLC.

ID: IN10GBCT005 CATEGORY: Clinical Trials GEOGRAPHY: UK AUTHOR: Vidhi Upadhyay

Buy Now

UK Neurology Clinical Trials Market Executive Summary

The UK Neurology Clinical Trials market is projected to grow from $342.2 Mn in 2022 to $451.4 Mn by 2030, registering a CAGR of 3.52% during the forecast period of 2022 - 2030. The NHS delivers high-quality treatment by global standards; the United Kingdom's healthcare system was placed 10th overall in the 2021 Global Index of Health Innovation. Healthcare costs around 18% of a citizen's income tax, or 4.5% of an ordinary citizen's income. In the United Kingdom, 600,000 people have epilepsy, accounting for around one in every 100 persons. Every day, 87 individuals are diagnosed. Currently, Parkinson's Disease affects 145,000 persons in the United Kingdom.

Neurology clinical trials are a significant field of study in the United Kingdom, with several studies now underway. Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke are among the conditions being examined. The National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) provides researchers with the practical assistance they need to make clinical trials happen in both the NHS and the broader healthcare and social care setting. The CRN funds research in 30 different speciality therapeutic areas. There are also various neurological research organisations in the UK, such as the UK Dementia Research Institute, Parkinson's UK, and the MS Society. In their particular areas of specialisation, these organisations invest in research as well as provide resources and assistance for clinical trials.

UK Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The UK has a solid clinical trial ecosystem, including a well-developed regulatory framework, a matrix of research centres and hospitals, and an engaged patient population. The significant worldwide burden of neurological illnesses has raised financial support and shareholders’ interest in supporting neurological clinical investigations is on the rise. The National Institute for Health Research (NIHR) funds and supports clinical trials in the UK and collaborates closely with the NHS to ensure that studies are carried out to the highest standards. Furthermore, the UK has a varied and active patient population, which makes it a desirable place for clinical studies. The UK is a thriving centre for neurology clinical trials, and it is expected to make substantial contributions to the progress of the management and understanding of neurological disorders.

Market Restraints

According to current data, the UK has lesser neurology consultants than other high-income nations. There have been concerns with regard to the impact on those with neurological problems obtaining timely access to health and care services. There are additionally more factors that may have an influence on the growth of neurology clinical trials in the UK. One such constraint is the increased struggle for financing, as many other areas of study demand funds as well. Also, the regulatory environment for clinical trials can be complicated and time-consuming, which can add to the cost and duration of investigations.

There is also the possibility that Brexit may have an influence on clinical trials in the UK, as the country's withdrawal from the EU will limit its capacity to partner with other nations and access specific funding sources.

Competitive Landscape

Global Key Players

Pfizer Inc.
Biogen Inc.
Novartis AG,
Roche Holding AG
Eli Lilly and Company
Sanofi SA
AstraZeneca PLC
Merck & Co. Inc
Johnson & Johnson Services, Inc.
GlaxoSmithKline PLC

Local Key Players

Cambridge Cognition Holdings PLC - Cambridge Cognition is a prominent neuroscience technology firm that uses scientifically established digital health solutions to improve cognitive assessment for improved brain health research
IXICO PLC - IXICO specialises in the gathering, optimization, and analytics of data for uncommon neurological conditions such as Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA)
Neuro-Bio Ltd. - Neuro-Bio is a privately held firm based at Oxford University that is focusing on the development of oral medications to treat Alzheimer's disease
Nodthera Ltd.- NodThera is a biotechnology business that treats chronic illnesses by addressing the cause of inflammation

Notable Insights

February 2023, Pfizer announced that Phase 3 data for Zavegepant for the Acute Management of Migraine in Adults was published in The Lancet Neurology.

November 2022, Biogen Inc. and Eisai Co., Ltd. announced the findings of Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta (A) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed amyloid pathology in the brain.

Healthcare Policies and Regulatory Landscape

The Medicines and Healthcare products Regulatory Agency is the regulatory authority in the UK in charge of clinical trials (MHRA). The MHRA guarantees that clinical trials are done safely and ethically and that the items being tested fulfil the appropriate quality, safety, and efficacy requirements.

Reimbursement Scenario

In the United Kingdom, clinical trials are funded by a variety of public and private organisations, including charities (typically focused on a specific disease), the UK government through organizations such as the National Institute for Health Research (NIHR) or the Medical Research Council (MRC), pharmaceutical companies, and international organisations.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.